T-1095

T-1095 is an orally active, synthetic phlorizin derivative that acts as a prodrug. Upon oral administration, it is metabolized in the liver to its active form, T-1095A. T-1095A is a non-selective sodium-glucose cotransporter (SGLT) inhibitor that targets both SGLT1 and SGLT2, with a higher selectivity for SGLT2. By inhibiting these transporters in the renal proximal tubules, T-1095 suppresses renal glucose reabsorption and promotes urinary glucose excretion (glucosuria), thereby lowering blood glucose and HbA1c levels in an insulin-independent manner. Originally developed by Tanabe Seiyaku (now Mitsubishi Tanabe Pharma) and licensed to Johnson & Johnson, T-1095 reached Phase II clinical trials for the treatment of type 2 diabetes mellitus. However, its development was discontinued due to safety concerns and gastrointestinal side effects associated with SGLT1 inhibition in the intestine, as well as the emergence of more selective SGLT2 inhibitors.

Other names

3-(5-benzofuranyl)-1-[2-hydroxy-6-[[6-O-(methoxycarbonyl)-beta-D-glucopyranosyl]oxy]-4-methylphenyl]-1-propanoneT-1095AT1095AT 1095A